 |
|
Retinal Toxicity of Human Tissue Plasminogen Activator in Vitrectomized Rabbit Eyes
W. David Irvine, MD;
Mark W. Johnson, MD;
Eleut Hernandez, LAT;
Karl R. Olsen, MD
Arch Ophthalmol. 1991;109(5):718-722.
Abstract
| |
• The retinal toxicity of human tissue plasminogen activator in normal rabbit eyes has recently been reported. We now report the retinal toxicity of tissue plasminogen activator in three groups of vitrectomized rabbit eyes. Group 1 underwent gas compression of the vitreous followed by tissue plasminogen activator injection in doses of 25, 50, and 100 µg (all doses were administered in 100 µL of fluid). Group 2 underwent lensectomy and vitrectomy followed by tissue plasminogen activator injection of 100 µg. Group 3 underwent lensectomy, vitrectomy, and complete fluid/gas exchange prior to injections of 12.5 and 25 µg of tissue plasminogen activator. Control eyes received 100 µL of balanced salt solution. In group 1, no retinal toxic reactions were observed after administration of 25 or 50 µg of tissue plasminogen activator, but all eyes receiving 100 µg demonstrated retinal damage on ophthalmoscopy, electroretinography, and light microscopy. In group 2, no retinal toxic reactions were seen after administration of 100 µg of tissue plasminogen activator. In group 3, two of 11 eyes receiving 25 µg of tissue plasminogen activator demonstrated toxic retinal changes by ophthalmoscopy, electroretinography, and light microscopy. These results suggest that gas compression of the vitreous does not significantly alter the toxic changes seen caused by tissue plasminogen activator. While lensectomy and vitrectomy appears to widen the therapeutic window for tissue plasminogen activator, the margin of safety is reduced with the addition of a large gas bubble.
Author Affiliations
From the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami (Fla) School of Medicine.
Footnotes
Accepted for publication February 14, 1991.
Read before the annual meeting of the Association for Research in Vision and Ophthalmology, Sarasota, Fla, May 2, 1990.
Reprint requests to the Bascom Palmer Eye Institute, PO Box 016880, Miami, FL 33101 (Dr Irvine).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Toxic Effects of Recombinant Tissue Plasminogen Activator on Cultured Human Corneal Endothelial Cells
Yoeruek et al.
IOVS 2008;49:1392-1397.
ABSTRACT
| FULL TEXT
Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion
Mahmoud et al.
Br J Ophthalmol 2006;90:911-915.
ABSTRACT
| FULL TEXT
A study of retinal penetration of intravitreal tenecteplase in pigs.
Kwan et al.
IOVS 2006;47:2662-2667.
ABSTRACT
| FULL TEXT
Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.
Singh et al.
Br J Ophthalmol 2006;90:429-431.
ABSTRACT
| FULL TEXT
Plasminogen activators promote excitotoxicity-induced retinal damage
Mali et al.
FASEB J. 2005;19:1280-1289.
ABSTRACT
| FULL TEXT
Treatment of Submacular Hemorrhage With Low-Dose Intravitreal Tissue Plasminogen Activator Injection and Pneumatic Displacement
Handwerger et al.
Arch Ophthalmol 2001;119:28-32.
ABSTRACT
| FULL TEXT
Retinal Toxicity of Commercial Intravitreal Tissue Plasminogen Activator Solution in Cat Eyes
Hrach et al.
Arch Ophthalmol 2000;118:659-663.
ABSTRACT
| FULL TEXT
Pneumatic Displacement of Subretinal Hemorrhage Without Tissue Plasminogen Activator
Ohji et al.
Arch Ophthalmol 1998;116:1326-1332.
ABSTRACT
| FULL TEXT
Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study
Heiligenhaus et al.
Br J Ophthalmol 1998;82:810-815.
ABSTRACT
| FULL TEXT
Evaluation of a Commercial Recombinant Tissue-Type Plasminogen Activator Preparation in the Subretinal Space of the Cat
Benner et al.
Arch Ophthalmol 1991;109:1731-1736.
ABSTRACT
|
